Merck Oncology Data Presentations at 2016 ASCO Annual Meeting

Abstracts involving key Merck Oncology and KEYTRUDA® (pembrolizumab) studies at this year’s 2016 ASCO Annual Meeting are listed below. Overall, researchers will present data evaluating KEYTRUDA as monotherapy or in combination with other therapies across more than 15 different cancers, including several new tumor types. For more information, including full abstracts, please visit the ASCO iPlanner website at https://iplanner.asco.org/AM2016/#/.

**KEYTRUDA (pembrolizumab)**

*Melanoma*

- **(Abstract #3013) Poster Session/Discussion:** Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC). M. Atkins. Sunday, June 5. Poster: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion: 4:45 p.m. – 6:00 p.m. CDT. Location: Hall B1.

- **(Abstract #3014) Poster Session/Discussion:** Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study. A. Ribas. Sunday, June 5. Poster: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion: 4:45 p.m. – 6:00 p.m. CDT. Location: Hall B1.

- **(Abstract #9503) Oral Session:** Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. C. Robert. Monday, June 6. 2:15 p.m. – 2:27 p.m. CDT (session begins at 1:15 p.m. CDT). Location: Arie Crown Theater.


- **(Abstract #9506) Oral Session:** Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. G. Long. Monday, June 6. 2:51 p.m. – 3:03 p.m. CDT (session begins at 1:15 p.m. CDT). Location: Arie Crown Theater.

- **(Abstract #9513) Poster Session/Discussion:** KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. A. Daud. Saturday, June 4. Poster: 1:00 p.m. – 4:30 p.m. CDT. Location: Hall A. Discussion: 4:45 p.m. – 6:00 p.m. CDT. Location: E354b.

- **(Abstract #9568) Poster Session:** Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. G. Long. Saturday, June 4. 1:00 p.m. – 4:30 p.m. CDT. Location: Hall A.
Lung Cancer

- **(Abstract #3030) Poster Session:** Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. R. Herbst. Sunday, June 5. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

- **(Abstract #9015) Poster Session/Discussion:** Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1-Positive NSCLC. P. Baas. Saturday, June 4. Poster: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion: 3:00 PM – 4:15 PM CDT. Location: E354b.

- **(Abstract #9016) Poster Session/Discussion:** Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. S. Gadgeel. Saturday, June 4. Poster: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion: 3:00 PM – 4:15 PM CDT. Location: E354b.

- **(Abstract #9024) Poster Session:** Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. E. Garon. Saturday, June 4. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

- **(Abstract #9026) Poster Session:** Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). R. Hui. Saturday, June 4. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

- **(Abstract #9027) Poster Session:** Phase II/III study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H. M. Gubens. Saturday, June 4. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

Head and Neck Cancer

- **(Abstract #6010) Clinical Science Symposium:** Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). L. Chow. Monday, June 6. 11:42 a.m. – 11:54 a.m. CDT (session begins at 11:30 a.m. CDT). Location: S100bc.

- **(Abstract #6011) Clinical Science Symposium:** Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). J. Bauml. Monday, June 6. 12:06 p.m. – 12:18 p.m. CDT (session begins at 11:30 a.m. CDT). Location: S100bc.

- **(Abstract #6012) Clinical Science Symposium:** Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012. R. Mehra. Monday, June 6. 12:18 p.m. – 12:30 p.m. CDT (session begins at 11:30 a.m. CDT). Location: S100bc.

- **(Abstract #6017) Poster Session/Discussion:** Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. R. Cohen. Saturday, June 4. Poster: 1:00 p.m. – 4:30 p.m. CDT. Location: Hall A. Discussion: 4:45 p.m. – 6:00 p.m. CDT. Location: S406.

- **(Abstract #6091) Poster Session:** Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. J. Mehnert. Saturday, June 4. 1:00 p.m. – 4:30 p.m. CDT. Location: Hall A.

Hematological Cancers

- **(Abstract #7555) Poster Session/Discussion:** Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. R. Chen. Monday, June 6. Poster: 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A. Discussion: 1:15 p.m. – 2:45 p.m. CDT. Location: E354b.

- **(Abstract #8010) Clinical Science Symposium:** Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis. M-V. Mateos. Tuesday, June 7. 10:09 a.m. – 10:21 a.m. CDT (session begins at 9:45 a.m. CDT). Location: E354b.
Gastrointestinal Cancer

- **(Abstract #4037) Poster Session:** Preliminary safety data from KEYNOTE-059: pembrolizumab plus 5-fluorouracil (5-FU) and cisplatin for first-line treatment of advanced gastric cancer. C. Fuchs. Saturday, June 4. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

- **(Abstract #4046) Poster Session:** Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. T. Doi. Saturday, June 4. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

- **(Abstract #4130) Poster Session:** A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC). M. Overman. Saturday, June 4. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

Gynecological Cancer

- **(Abstract #5515) Oral Abstract Session:** Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the Phase 1b KEYNOTE-028 study. J-S. Frenel. Sunday, June 5. 10:09 a.m. – 10:21 a.m. CDT (session begins at 9:45 a.m. CDT). Location: E450ab.

- **(Abstract #5581) Poster Session/Discussion:** Pembrolizumab in advanced endometrial cancer: preliminary results from the phase 1b KEYNOTE-028 study. P. Ott. Monday, June 6. Poster: 1:00 p.m. – 4:30 p.m. CDT. Location: Hall A. Discussion: 4:45 p.m. – 6:00 p.m. CDT. Location: S100bc.

Additional Cancers

- **(Abstract #3002) Oral Abstract Session:** Phase Ib study of PF-0582566 in combination with pembrolizumab in patients with advanced solid tumors. A. Tolcher. Saturday, June 4. 1:39 p.m. – 1:51 p.m. CDT (session begins at 1:15 p.m. CDT). Location: Hall B1.

- **(Abstract #3034) Poster Session:** Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System. B. Wallden. Sunday, June 5. 8:00 a.m. – 11:30 a.m. CTD. Location: Hall A.

- **(Abstract #3056) Poster Session:** A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. R. Herbst. Sunday, June 5. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

OTHER MERCK ONCOLOGY MEDICINES

- **(Abstract #3044) Poster Session:** Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity. G. Markel. Sunday, June 5. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

- **(Abstract #10579) Poster Session:** Randomized, placebo-controlled, phase III study of aprepitant in preventing chemotherapy-induced nausea and vomiting in children: Analysis by age group. H-J. Kang. Monday, June 6. 8:00 a.m. – 11:30 a.m. CDT. Location: Hall A.

For additional information on Merck Oncology, visit [http://www.mercknewsroom.com/oncology-infocenter](http://www.mercknewsroom.com/oncology-infocenter).

Investigator-initiated / investigator-sponsored studies not included in this document.